SINGLE USE SYSTEM IN BIOPHARMA MANUFACTURING MARKET ANALYSIS

Single Use System in Biopharma Manufacturing Market, By Bioreactors (Less than 1000L, 1000-2000L, and More than 2000L), By Application (Filtration, Storage (Buffer & Media Storage, Freeze & Thaw), Cell Culture, Mixing, Purification, and Aseptic Filling), By Bioprocessing (Small-scale, Mid-scale, and Large-scale), By Product (Sampling Systems, Bioprocess Containers, Bioreactors, Mixers, Membrane Absorbers, Bottles, Equipment, Transfer Units, and Others (Disposable filter Cartridges (DFC), Depth Filters, Clamps etc.)), By Modality (Protein & Monoclonal Antibody (Mab), Cell Therapy, Gene Therapy, Conventional Vaccine, and mRNA), By Component (Drug Substance and Drug Product), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Sep 2022
Code : CMI5228
Pages :174
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Global Single Use System in Biopharma Manufacturing Market: Regional Insights

Based on geography, the global single use system in biopharma manufacturing market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the expanding biopharmaceutical R&D coupled with the presence of large-scale biopharmaceutical manufacturing facilities in the region, especially in the United States. For instance, in January 2021, Fujifilm planned to invest over 200 Billion yen (US$ 2 Billion) to establish new manufacturing site for biopharmaceuticals in the U.S., as well as to accelerate the growth of its biopharmaceutical contract development and manufacturing business.

Moreover, Asia Pacific is expected to witness robust growth in the global single use system in biopharma manufacturing market due to growing biopharmaceutical manufacturing industry. For instance, in recent years, China and India have emerged as a potential market for single-use technology with growing biopharmaceutical manufacturing industry. In November 2021, WuXi Biologics announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China. This facility serves as an example of WuXi Biologics’ implementation of single-use technology.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa